Health Care · Biological Products, (No Diagnostic Substances)

CMPX Compass Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 173802187 filings
Russell 2000

CMPX at a glance

Compass Therapeutics, Inc. (CMPX, SEC CIK 1738021) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 20, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Compass Therapeutics, Inc. (CMPX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $66.5 million. Diluted EPS was -$0.42.
  • As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Compass Therapeutics, Inc. (CMPX) shares worth $49.4 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Lerner Neil on November 17, 2026 of 10,000 shares at $0.59 per share.
  • In the last 90 days, CMPX insiders reported 3 open-market purchases ($27K) and 0 open-market sales ($0) on Form 4, a net purchase of $27K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
−100.0% vs prior year
Insiders · 90 days
3 buys · 0 sells
Net +$27K
13F holders
25 funds
$49.4M · −1 vs prior quarter
Latest 8-K
Nov 20, 2026
Item 3.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales generated
  • Operating margin -107.0% vs -110.9% YoY, based on operating losses of $28.8 million and $15.8 million
  • Tovecimig highest R&D spending, $14.4 million vs $3.3 million YoY
  • Cash, equivalents and marketable securities $163 million, funding operations into 2028
  • Operating cash use $48.3 million, up from $35.9 million YoY; FDA recommended survival-benefit trial before tovecimig BLA

Risk Factors

  • New corporate-governance risk: bylaws adopted exclusive Delaware and Massachusetts forums for specified stockholder litigation
  • Regulatory and legal risk: Securities Act claims restricted to U.S. District Courts in Delaware or Massachusetts
  • Macroeconomic risk: July 2026 U.S. tariffs of approximately 10% to 12.5% increased potential research and development costs
  • Operational risk: macroeconomic disruptions could delay clinical-trial initiation or expansion and material supply availability
  • Financial risk: deteriorating equity and credit markets could make future financing costlier, more dilutive, or unavailable

AI summary of the CMPX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 20, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days
  • Immediate delisting not triggered: shares continue trading on Nasdaq Capital Market
Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Compass Therapeutics’ quarter and nine months ended September 30, 2026
  • Financial results and management commentary are contained in Exhibit 99.1, relevant for assessing operating performance and cash position

Item EX-99.1: Item EX-99.1

  • Q3 net loss $27.2M, or $0.15 per share, versus $14.3M, or $0.08, as pipeline investment accelerated
  • Cash and marketable securities $163M, down from $209M at December 31, 2025, funding operations into 2028
Filed Sep 22, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • FDA regulatory feedback on tovecimig in biliary tract cancer, a potential second-line treatment path
  • COMPANION-002 Phase 2/3 data planned for FDA discussion before a potential BLA submission

AI summaries of CMPX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CMPX

Don't miss the next CMPX filing

  • Alerts as it files. A push when CMPX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CMPX, by share count.
  • Ask anything. An AI agent that reads every CMPX filing and answers with sources.

CMPX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Lerner NeilBuyNov 17, 2026$0.59
Lerner NeilBuyOct 1, 2026$0.92
Lerner NeilBuySep 24, 2026$1.14
Anderman JonathanAApr 29, 2026$1.89
Anderman JonathanBuyApr 29, 2026$1.89
Lerner NeilAApr 29, 2026$1.89
Lerner NeilBuyApr 29, 2026$1.89
Schuetz Thomas J.FFeb 8, 2026$6.52

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$850K$0
Operating Income-$50.4M-$56.6M-$72.8M
Net Income-$42.5M-$49.4M-$66.5M
Op. Margin--6661.8%-
Net Margin--5808.8%-
Balance Sheet
Total Assets-$140.4M$219.6M
Equity-$125.2M$196.8M
ROE--39.4%-33.8%
Per Share
EPS$-0.33$-0.36$-0.42
Cash Flow
Operating CF-$40.6M-$44.9M-$49.1M
CapEx-$44K$25K

Source: XBRL data in Compass Therapeutics, Inc. (CMPX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CMPX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CMPX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202625$49.4M
Q2 202626$118.8M
Q1 202629$200.1M
Q4 202525$219.5M
Q3 202521$146.6M
Q2 202524$84.3M
Q1 202522$51.6M
Q4 202414$32.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CMPX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 20, 2026Analysis-
4Nov 18, 2026--
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
4Oct 2, 2026--
4Sep 25, 2026--
8-KSep 22, 2026Analysis-
SC 13GAug 7, 2026-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
8-KJul 1, 2026Analysis-
8-KJun 23, 2026Analysis-
8-KJun 11, 2026Analysis-
10-QMay 5, 2026Analysis
8-KMay 5, 2026Analysis-
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 29, 2026--
4Apr 29, 2026--
8-KApr 27, 2026Analysis-
10-KMar 5, 2026-
8-KMar 5, 2026Analysis-
4Feb 10, 2026-
SC 13GJan 21, 2026-
4Jan 12, 2026-

Related Health Care companies

All Health Care →

CMPX SEC filings: frequently asked questions

Are CMPX insiders buying or selling?

In the last 90 days, Compass Therapeutics, Inc. (CMPX) officers, directors and 10% owners reported 3 open-market purchases worth $27,150 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CMPX stock?

As of September 30, 2026, the largest Compass Therapeutics, Inc. (CMPX) holders among the 13F filers tracked by SignalX were BlackRock ($11.9 million), State Street Corp ($8.0 million), Vanguard Capital Management LLC ($6.2 million), Millennium Management ($4.9 million), Goldman Sachs Group ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was CMPX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Compass Therapeutics, Inc. (CMPX) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $66.5 million. Diluted EPS was -$0.42. The figures come from the XBRL data in the 10-K.

What did CMPX report in its latest 8-K?

Compass Therapeutics, Inc. (CMPX) filed an 8-K on November 20, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days.

What are the latest CMPX SEC filings?

Compass Therapeutics, Inc. (CMPX) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 20, 2026 and a Form 4 insider filing on November 18, 2026.

What is CMPX's SEC CIK number?

Compass Therapeutics, Inc. (CMPX)'s SEC Central Index Key (CIK) is 1738021. EDGAR lists every CMPX filing under that number.

Ask anything about CMPX

The research agent reads CMPX's filings, financials, insider trades and 13F holders, then answers with sources.